Basel Karim

Development of Potent and Selective CK1α Molecular Glue Degraders | Journal of Medicinal Chemistry pubs.acs.org/doi/abs/10.102…

We are seeking a talented Postdoctoral Research Fellow to join our group within Amgen’s Induced Proximity Platform. please apply below! #TPD, #PROTAC, #Chemicalbiology #ChemicallyInducedProximity, #IndustryPostdoc #InducedProximityPlatform amgen.wd1.myworkdayjobs.com/Careers/job/US…

Ashvattha is the first therapeutics platform to target and reprogram macrophage and microglia (two important immune cells) which are known to be responsible for neurological disorders to cancer, ophthalmic diseases to autoimmune disorders. We're excited to partner with @tribecap and @arjunsethi for our $50M Series B extension. Thankful to @NatCapCentral for their support since our incubation! /1

Today, Arc announced it is joining forces with @NVIDIAHealth to develop powerful computational tools that will help researchers everywhere explore and understand living systems in ways previously impossible. arcinstitute.org/news/news/arc-…

Congrats to @SojungKim20, our collaborator Jordan(@Sigman_Lab), our collaborators from Merck and former group members Justin & Yasuki on the publication of our work on understanding the enantioselectivity of our photomediated ring contraction in @J_A_C_S! doi.org/10.1021/jacs.4…

PMV Pharma is First to the Clinic With a p53(Y220C) Mutant Stabilizer, and Early Results Show Promise | drughunters.com/3DncQVq PMV pharma are the first to enter the clinic with their p53(Y220C) stabilizer/reactivator, rezatapopt.

Delighted to share our #NightScience tale: "A tetramer of BCL11A is required for stable protein production & fetal hemoglobin silencing," in @ScienceMagazine. Co-led by Zheng Ge, Yin Maolu, & me, here’s a tweetorial about our puzzle-solving adventure! 1/7 tinyurl.com/2tpaaua3

Awesome paper from Jack Taunton’s lab ⁦@UCSF⁩ : Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation | Nature nature.com/articles/s4158…

Gilead Utilizes A Counterintuitive Approach to Improve the Metabolic Stability of an HIV Protease Inhibitor | drughunters.com/4eXsbd5 Disclosed at the Fall 2024 ACS meeting in Denver, the structure and discovery story of Gilead's elunonavir is available to read on Drug Hunter

Really nice new cancer drug modality: Chemical induction of proximity to hijack the activity of a cancer driver! From @RomanSarott @saigourisankar @baselakarim in the Gray & Crabtree labs @Stanford

In this work, @alessiociulli, @dlzollman, and @UoDCeTPD design and validate a truncated CRBN construct, CRBNmidi, that enables crystallization and biophysical characterization of CRBN-binding ligands and degraders. #TPD #PROTAC nature.com/articles/s4146…

Mechanistic and structural insights into degrader-targeted protein ubiquitinability, now out in @ScienceAdvances! science.org/doi/10.1126/sc… Let's make more degraders that hit the bull's eye 🎯 @alessiociulli @UoDCeTPD

Thrilled to share our latest preprint describing discovery of the charged, metabolically activated molecular glue degrader engaging the basic pocket of the structural CRBN homolog, YPEL5 - a subunit of the giant GID/CTLH E3 ligase!!! biorxiv.org/content/10.110…

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases dlvr.it/TDQ5zm

@tineisadora @Nature L E T S G O 🫡 🫣 🦅

🚋TRAMs 🚋is now out in @Nature ! 🥳How do we move proteins from one subcellular space to another in a targeted + modular fashion, and what does this entail for the cell? Check it out! ⬇️⬇️⬇️

Let’s play a little game. Let’s say that you’re the CSO at a cancer pharma company, and you have to choose a target to go after. Here’s a gene – high expression is associated with poor prognosis in brain cancer. Looks like a good candidate for an inhibitor right?

You see our bottle? We keep it very classy, very mindful, very demure.

Targeting the “Impossible” Asp12 of KRAS(G12D)(ON) with an Aziridine-Containing Tri-complex | drughunters.com/3WqUOr2 RMC-9805 is a first-in-class, covalent KRAS(G12D)(ON) molecular glue inhibitor from @Revolution Medicines. Read the full article on Drug Hunter